Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aurora Cannabis Inc T.ACB

Alternate Symbol(s):  T.ACB.WS.U | ACB

Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company's principal business lines are focused on the production, distribution, and sale of cannabis related products in Canada and internationally. The Company’s segments include Canadian Cannabis, European Cannabis and Plant Propagation. The Company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being and Greybeard, as well as CBD brands, Reliva and KG7. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol and CraftPlant. Its cannabis products are primarily cultivated and manufactured in the facilities in Edmonton, Alberta; Bradford Ontario; Pemberton, British Columbia, and Odense, Denmark. The Company is focused on offering its cannabis products to global medical cannabis market, recreational cannabis market and global hemp-derived cannabidiol (CBD) markets.


TSX:ACB - Post by User

Bullboard Posts
Post by coincollector87on Sep 14, 2018 9:57am
49 Views
Post# 28619620

Everyone Forget About PI? See Link:

Everyone Forget About PI? See Link:https://www.cantechletter.com/2018/09/aurora-cannabis-gets-new-15-00-price-target-at-pi-financial/

Aurora Cannabis gets new $15.00 price target at PI Financial

 BY 

Following the announcement of a major acquisition, PI Financial analyst Jason Zandberg has raised his price target on Aurora Cannabis (Quote, Chart TSX:ACB).

This morning, ACB announced it would acquire ICC Labs for $1.95 a share, or a total value of about $290-million.

“ICC is an ideal partner for Aurora to establish leadership in the South American cannabis market, delivering clear first mover advantage on a continent with over 420 million people,” Aurora CEO Terry Booth said. “ICC and its management team have shown exceptional vision and execution across production, expansion, distribution and product development. The company has a very strong management team with deep connections throughout the continent, which we believe will facilitate successful expansion into all South American markets.”

Zandberg gives the thumbs-up to the arrangement.

“This acquisition provides ACB with a strong presence in South America which has global opportunities,” he says. “Many Canadian LPs have made investments internationally but ICC Labs management not only have an operating history but have high level connections to many Latin American countries which have already translated into supply agreements (Mexico, Brazil for example).”

In a research update to clients today, Zandberg maintained his “Buy” rating on Aurora Cannabis, but raised his one-year price target on the stock from $13.00 to $15.00, implying a return of 84.7 per cent at the time of publication.

The analyst thinks ACB will generate EBITDA of negative $34.9-million on revenue of $64.5-million in fiscal 2018. He expects those numbers will improve to EBITDA of positive $80.8-million on a topline of $463.5-million the following year.

Zandberg warns that there is one cavaet to his more bullish target.

“We caution investors that a broad correction in equity valuations in the sector will negatively impact our target and recommendation,” he says. “Our ACB target represents an EV/EBITDA multiple of 44.2x based on our FY20 EBITDA (previously 41.2x).”

  •  
  •  
  •  
  •  
  •  

Bullboard Posts